SG10201601719RA - Anti-LAG-3 Antibodies - Google Patents

Anti-LAG-3 Antibodies

Info

Publication number
SG10201601719RA
SG10201601719RA SG10201601719RA SG10201601719RA SG10201601719RA SG 10201601719R A SG10201601719R A SG 10201601719RA SG 10201601719R A SG10201601719R A SG 10201601719RA SG 10201601719R A SG10201601719R A SG 10201601719RA SG 10201601719R A SG10201601719R A SG 10201601719RA
Authority
SG
Singapore
Prior art keywords
lag
antibodies
Prior art date
Application number
SG10201601719RA
Inventor
Cheng-I Wang
Siok Ping Yeo
Chia Yin Lee
Hsueh Ling Janice Oh
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG10201601719RA priority Critical patent/SG10201601719RA/en
Priority to JP2018546454A priority patent/JP2019517773A/en
Priority to TW106107003A priority patent/TW201734042A/en
Priority to AU2017226965A priority patent/AU2017226965A1/en
Priority to PCT/EP2017/055060 priority patent/WO2017149143A1/en
Priority to CN201780015245.3A priority patent/CN109219619A/en
Priority to SG11201807252QA priority patent/SG11201807252QA/en
Priority to EP17710682.0A priority patent/EP3423492A1/en
Priority to CA3015938A priority patent/CA3015938A1/en
Priority to KR1020187028534A priority patent/KR20180114218A/en
Priority to US16/079,947 priority patent/US20190040136A1/en
Publication of SG10201601719RA publication Critical patent/SG10201601719RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10201601719RA 2016-03-04 2016-03-04 Anti-LAG-3 Antibodies SG10201601719RA (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SG10201601719RA SG10201601719RA (en) 2016-03-04 2016-03-04 Anti-LAG-3 Antibodies
JP2018546454A JP2019517773A (en) 2016-03-04 2017-03-03 Anti-LAG-3 antibody
TW106107003A TW201734042A (en) 2016-03-04 2017-03-03 Anti-LAG-3 antibodies
AU2017226965A AU2017226965A1 (en) 2016-03-04 2017-03-03 Anti-LAG-3antibodies
PCT/EP2017/055060 WO2017149143A1 (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies
CN201780015245.3A CN109219619A (en) 2016-03-04 2017-03-03 anti-LAG-3 antibody
SG11201807252QA SG11201807252QA (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies
EP17710682.0A EP3423492A1 (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies
CA3015938A CA3015938A1 (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies
KR1020187028534A KR20180114218A (en) 2016-03-04 2017-03-03 Anti-LAG-3 antibody
US16/079,947 US20190040136A1 (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201601719RA SG10201601719RA (en) 2016-03-04 2016-03-04 Anti-LAG-3 Antibodies

Publications (1)

Publication Number Publication Date
SG10201601719RA true SG10201601719RA (en) 2017-10-30

Family

ID=58277259

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201601719RA SG10201601719RA (en) 2016-03-04 2016-03-04 Anti-LAG-3 Antibodies
SG11201807252QA SG11201807252QA (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201807252QA SG11201807252QA (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies

Country Status (10)

Country Link
US (1) US20190040136A1 (en)
EP (1) EP3423492A1 (en)
JP (1) JP2019517773A (en)
KR (1) KR20180114218A (en)
CN (1) CN109219619A (en)
AU (1) AU2017226965A1 (en)
CA (1) CA3015938A1 (en)
SG (2) SG10201601719RA (en)
TW (1) TW201734042A (en)
WO (1) WO2017149143A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI756187B (en) 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
EA201991673A1 (en) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. LAB3-labeled RADIOACTIVE ISOTOPE ANTIBODIES FOR IMMUNO-PET VISUALIZATION
BR112019020610A2 (en) 2017-05-30 2020-04-22 Bristol-Myers Squibb Company treatment of positive tumors for lag-3
CA3060989A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
CN110678200B (en) 2017-05-30 2024-05-17 百时美施贵宝公司 Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
SG11202004172UA (en) 2017-11-10 2020-06-29 Agency Science Tech & Res Il2rbeta/common gamma chain antibodies
JP7438180B2 (en) * 2018-03-20 2024-02-26 ウーシー バイオロジクス アイルランド リミテッド Novel anti-LAG-3 antibody polypeptide
CN110343178B (en) * 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 Anti-human LAG-3 monoclonal antibody and application thereof
EP3796977A4 (en) * 2018-05-17 2022-03-02 The Board of Trustees of the Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
SG11202100693UA (en) 2018-07-26 2021-02-25 Bristol Myers Squibb Co Lag-3 combination therapy for the treatment of cancer
EA202191086A1 (en) 2018-10-19 2021-09-20 Бристоль-Мейерз Сквибб Компани COMBINED MELANOMA THERAPY
WO2020094836A1 (en) 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
TW202031683A (en) 2018-11-09 2020-09-01 新加坡商優其洛伊生物私人有限公司 Il2rbeta/common gamma chain antibodies
KR102662915B1 (en) * 2018-11-22 2024-05-03 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 anti-B7-H3 antibody
GB201906118D0 (en) * 2019-05-01 2019-06-12 Immutep S A Anti-LAG-3 binding molecules
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
JP2022534967A (en) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー Multiple tumor gene signatures and their uses
CN114127315A (en) 2019-05-30 2022-03-01 百时美施贵宝公司 Method of identifying subjects suitable for immunooncology (I-O) therapy
IL267614A (en) * 2019-06-24 2019-09-26 Lotem Michal Nucleic acid agents modulating slamf6 isoforms
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
KR20220066334A (en) 2019-09-22 2022-05-24 브리스톨-마이어스 스큅 컴퍼니 Quantitative spatial profiling for LAG-3 antagonist therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
KR20220093349A (en) 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 LAG-3 antagonist therapy for melanoma
EP4100426A1 (en) 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Il-10 and uses thereof
KR102555328B1 (en) * 2020-02-06 2023-07-17 아주대학교산학협력단 T cell receptor-like antibody to CMV pp65 peptide presented by HLA-A*02 and uses thereof
MX2023000197A (en) 2020-07-07 2023-02-22 BioNTech SE Therapeutic rna for hpv-positive cancer.
BR112023003427A2 (en) 2020-08-28 2023-03-21 Bristol Myers Squibb Co LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA
BR112023003553A2 (en) 2020-08-31 2023-04-04 Bristol Myers Squibb Co CELLULAR LOCATION AND IMMUNOTHERAPY SIGNATURE
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
KR20240005700A (en) 2021-03-29 2024-01-12 주노 쎄러퓨티크스 인코퍼레이티드 Dosing and Treatment Methods Using Combination of Checkpoint Inhibitor Therapy and CAR T Cell Therapy
WO2022240741A1 (en) 2021-05-12 2022-11-17 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
AU2022375806A1 (en) 2021-10-29 2023-12-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131003A1 (en) 1992-05-26 1993-12-09 Raymond G. Goodwin Novel cytokine that binds cd30
ITRM20010408A1 (en) 2001-07-10 2003-01-10 Univ Napoli Federico Ii CYTOTOXIC HUMAN MINI-ANTIBODY FOR CANCER CELLS THAT EXPRESS THE ERBB2 RECEPTOR.
NZ534174A (en) 2002-01-09 2007-03-30 Medarex Inc An isolated human monoclonal antibody which binds to human CD30
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
DK2287195T3 (en) 2004-07-01 2019-08-19 Innate Pharma PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND USE IN DIAGNOSTICS AND THERAPY
SI2567976T1 (en) 2005-03-23 2017-11-30 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
CN109485727A (en) 2005-05-09 2019-03-19 小野药品工业株式会社 The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody
TWI461436B (en) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human monoclonal antibody human cd134 (ox40) and methods of making and using same
PL2511301T3 (en) 2006-08-04 2018-05-30 Medimmune Limited Human antibodies to erbb 2
CA2669520C (en) 2006-11-13 2016-07-26 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using sirna molecules directed against cd24
SI2129396T1 (en) 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
US9244059B2 (en) * 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) * 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
AU2008334063A1 (en) 2007-11-30 2009-06-11 Bristol-Myers Squibb Company Anti-B7H4 monoclonal antibody-drug conjugate and methods of use
AR072999A1 (en) * 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
TWI686405B (en) 2008-12-09 2020-03-01 建南德克公司 Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CA2800488A1 (en) 2010-05-26 2011-12-01 Regents Of The University Of Minnesota Single-chain variable fragment anti-cd133 antibodies and uses thereof
CN103221427B (en) 2010-08-23 2016-08-24 德克萨斯州立大学董事会 Anti-OX40 antibody and the method using it
CA2834136C (en) 2011-04-25 2018-04-17 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
ES2694153T3 (en) 2011-09-30 2018-12-18 Regeneron Pharmaceuticals, Inc. Antibodies anti-ErbB3 and uses thereof
ES2861435T3 (en) 2011-11-03 2021-10-06 Univ Pennsylvania Specific compositions of isolated B7-H4 and methods of using them
JP6368308B2 (en) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ VISTA modulators for cancer diagnosis and treatment
EP2912063A1 (en) 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
EP2934575A2 (en) 2012-12-19 2015-10-28 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
ES2814962T3 (en) 2013-02-20 2021-03-29 Novartis Ag Efficient targeting of primary human leukemia using anti-CD123 chimeric antigen receptor modified T cells
AU2014230741B2 (en) * 2013-03-15 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
HUE044730T2 (en) 2013-09-20 2019-11-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
DK3087098T3 (en) 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista antibodies and fragments

Also Published As

Publication number Publication date
CN109219619A (en) 2019-01-15
CA3015938A1 (en) 2017-09-08
WO2017149143A1 (en) 2017-09-08
SG11201807252QA (en) 2018-09-27
TW201734042A (en) 2017-10-01
JP2019517773A (en) 2019-06-27
US20190040136A1 (en) 2019-02-07
AU2017226965A1 (en) 2018-10-11
EP3423492A1 (en) 2019-01-09
KR20180114218A (en) 2018-10-17

Similar Documents

Publication Publication Date Title
ZA201900373B (en) Anti-tim-3 antibodies
HK1253507A1 (en) Anti-ror1 antibodies
HK1254836A1 (en) Anti-ror1 antibodies
HK1256116A1 (en) Anti-lag-3 antibodies
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
GB201521393D0 (en) Antibodies
GB201521391D0 (en) Antibodies
IL253633A0 (en) Anti-transthyretin antibodies
HK1246804A1 (en) Tau-binding antibodies
GB201521382D0 (en) Antibodies
HK1255056A1 (en) Anti-cd115 antibodies
HUE059592T2 (en) Anti-transthyretin antibodies
GB201610044D0 (en) Antibodies
GB201603291D0 (en) Antibodies
GB201508180D0 (en) Antibodies
IL264262A (en) Anti-il-22r antibodies
GB201616699D0 (en) Antibodies
GB201509907D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
IL260083A (en) Anti-myl9 antibody
GB201522394D0 (en) Antibodies
GB201503438D0 (en) Antibodies
GB201622197D0 (en) Antibodies